Clinical Scorecard: Avacincaptad Pegol and Anti-VEGF in Real-World Practice
At a Glance
| Category | Detail |
|---|---|
| Condition | neovascular age-related macular degeneration (nAMD) and choroidal neovascularization (CNV) |
| Key Mechanisms | Concomitant use of anti-VEGF therapy with avacincaptad pegol |
| Target Population | Patients aged 50 years or older with geographic atrophy |
| Care Setting | Real-world clinical practice |
Key Highlights
- Analysis of over 13,000 eyes from the IRIS Registry
- Concomitant anti-VEGF therapy did not significantly alter avacincaptad pegol treatment patterns
- Average of 3.9 injections for eyes receiving anti-VEGF vs. 3.6 for those not receiving it
- Discontinuation rates were 10.8% with anti-VEGF and 6.7% without
- Treatment-emergent adverse events reported in 3.8% of eyes with anti-VEGF
Guideline-Based Recommendations
Diagnosis
- Assess for nAMD and CNV in patients with geographic atrophy
Management
- Consider avacincaptad pegol with or without concomitant anti-VEGF therapy
Monitoring & Follow-up
- Monitor treatment-emergent adverse events and injection frequency
Risks
- Higher rates of CNV and nAMD adverse events in eyes receiving anti-VEGF
Patient & Prescribing Data
10,181 patients aged 50 years or older
Concomitant anti-VEGF therapy is common but does not significantly affect avacincaptad pegol treatment patterns
Clinical Best Practices
- Evaluate the need for anti-VEGF therapy prior to initiating avacincaptad pegol
- Maintain regular follow-up to assess treatment efficacy and safety
- Educate patients on potential adverse events associated with treatment
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.